NCT04675450View on ClinicalTrials.gov

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

January 30, 2025

Conditions
Breast CancerPeripheral Neuropathy
Interventions
DRUG

Placebo

Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing

DRUG

NBP Softgel Capsules

Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.

Sponsors
All Listed Sponsors
collaborator

CSPC-NBP Pharmaceutical Co., Ltd.

INDUSTRY

lead

Conjupro Biotherapeutics, Inc.

INDUSTRY

NCT04675450 - NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy | Biotech Hunter | Biotech Hunter